CD19 and neoplasm: The persistent expression of CAR in tumor cells implies sustained blockade of the CD19 antigen; therefore, modifying T cells to transiently express CAR using nonintegrating gene vectors such as mRNA and minicircle DNA vectors can be utilized (73, 74).